[go: up one dir, main page]

AU2001245397A1 - Lipid metabolism enzymes - Google Patents

Lipid metabolism enzymes

Info

Publication number
AU2001245397A1
AU2001245397A1 AU2001245397A AU4539701A AU2001245397A1 AU 2001245397 A1 AU2001245397 A1 AU 2001245397A1 AU 2001245397 A AU2001245397 A AU 2001245397A AU 4539701 A AU4539701 A AU 4539701A AU 2001245397 A1 AU2001245397 A1 AU 2001245397A1
Authority
AU
Australia
Prior art keywords
lipid metabolism
metabolism enzymes
enzymes
lipid
metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245397A
Other languages
English (en)
Inventor
Debopriya Das
Ameena R. Gandhi
April Hafalia
Jennifer L. Hillman
Farrah A. Khan
Preeti Lal
Danniel B. Nguyen
Jennifer L. Policky
Y. Tom Tang
Catherine M. Tribouley
Narinder K. Walia
Monique G. Yao
Henry Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Publication of AU2001245397A1 publication Critical patent/AU2001245397A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
AU2001245397A 2000-03-02 2001-02-28 Lipid metabolism enzymes Abandoned AU2001245397A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18648000P 2000-03-02 2000-03-02
US60186480 2000-03-02
US19041500P 2000-03-17 2000-03-17
US60190415 2000-03-17
US19843700P 2000-04-19 2000-04-19
US60198437 2000-04-19
PCT/US2001/006771 WO2001064907A2 (fr) 2000-03-02 2001-02-28 Enzymes metabolisant les lipides

Publications (1)

Publication Number Publication Date
AU2001245397A1 true AU2001245397A1 (en) 2001-09-12

Family

ID=27392110

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245397A Abandoned AU2001245397A1 (en) 2000-03-02 2001-02-28 Lipid metabolism enzymes

Country Status (6)

Country Link
US (2) US7368270B2 (fr)
EP (1) EP1259621A2 (fr)
JP (1) JP2003525048A (fr)
AU (1) AU2001245397A1 (fr)
CA (1) CA2401660A1 (fr)
WO (1) WO2001064907A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002762A1 (fr) * 2000-07-03 2002-01-10 Mochida Pharmaceutical Co., Ltd. Nouvelle lipase
EP1446014A4 (fr) * 2001-10-01 2004-12-08 Univ Emory Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques
AU2003218668A1 (en) * 2002-02-27 2003-09-09 Bayer Healthcare Ag Regulation of human lipase
WO2007045660A1 (fr) * 2005-10-19 2007-04-26 Novartis Ag Phospholipase a2 secretee du groupe iii (spla2-iii) destinee a des traitement et diagnostic
CN111693701A (zh) * 2020-07-11 2020-09-22 成都益安博生物技术有限公司 一种大肠癌的外周血tcr标志物序列及其检测试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US6508825B1 (en) * 1997-02-28 2003-01-21 Lumend, Inc. Apparatus for treating vascular occlusions
US6749617B1 (en) * 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6197324B1 (en) * 1997-12-18 2001-03-06 C. R. Bard, Inc. System and methods for local delivery of an agent
US20030037350A1 (en) * 1999-09-29 2003-02-20 Millennium Pharmaceuticals, Inc. Novel nucleic acid sequences encoding a human ubiquitin protease, lipase, dynamin, short chain dehydrogenase, and ADAM-TS metalloprotease and uses therefor
US6394956B1 (en) * 2000-02-29 2002-05-28 Scimed Life Systems, Inc. RF ablation and ultrasound catheter for crossing chronic total occlusions
WO2003028756A2 (fr) * 2001-10-01 2003-04-10 Strauss Bradley H Utilisation de collagenase pour faciliter le croisement de fil-guide dans des occlusions arterielles totales
CA2505576A1 (fr) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Dispositif medical extensible et procede de traitement d'occlusions totales chroniques par administration locale d'un facteur angiogenique
WO2005089850A2 (fr) * 2004-03-19 2005-09-29 Medtronic Vascular, Inc. Dispositif et methode de traitement d'occlusions chroniques totales
WO2005094540A2 (fr) * 2004-03-25 2005-10-13 Hong Mun K Dispositif permettant de faciliter la recanalisation des occlusions totales
US7820732B2 (en) * 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices

Also Published As

Publication number Publication date
US7368270B2 (en) 2008-05-06
WO2001064907A2 (fr) 2001-09-07
EP1259621A2 (fr) 2002-11-27
CA2401660A1 (fr) 2001-09-07
US20090274680A1 (en) 2009-11-05
JP2003525048A (ja) 2003-08-26
WO2001064907A3 (fr) 2002-06-06
US20070082341A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
AU4211600A (en) Modified lipid production
AU2002216470A1 (en) Cholesterol lowering supplement
AU2001277969A1 (en) Direct internet advertising
AU2001288754A1 (en) Multiple advertising
AU1878601A (en) Enzyme
AU2002357860A1 (en) Enzymes
AU2001247049A1 (en) Autostereoscopic display
AU2001264055A1 (en) Display assembly
AU5101599A (en) Tetrahydrofolate metabolism enzymes
AU2001281636A1 (en) Advertising
AU2001227900A1 (en) Drug metabolizing enzymes
AU2001274981A1 (en) Drug metabolizing enzymes
AU5018900A (en) Lipid metabolism transcription factor
AU2001231053A1 (en) Lipid metabolism enzymes
AU2001270303A1 (en) Drug metabolizing enzymes
AU2001294245A1 (en) Compositions for improving lipid metabolism
AU2002347778A1 (en) Enzymes
AU2001245397A1 (en) Lipid metabolism enzymes
AU2001255324A1 (en) Drug metabolizing enzymes
AU2001235000A1 (en) Drug metabolizing enzymes
AU2001261424A1 (en) Lipid metabolism enzymes
AU2001273235A1 (en) Lipid metabolism molecules
AU2002211005A1 (en) Lipid peroxide-lowering compositions
AU2001257427A1 (en) Rna metabolism proteins
AU2001278154A1 (en) Drug metabolizing enzymes